ClinicalTrials.gg
CompletedNCT00293787Updated Feb 14, 2012

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

A Phase 3 interventional study of Travoprost 0.004% / Timolol 0.5% Ophthalmic Solution and Timolol Vehicle in Open-angle Glaucoma and Ocular Hypertension, sponsored by Alcon Research. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-02-14.

Sponsored by Alcon Research (part of Alcon) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.

Enrollment
21st of 45
156 · median 135
Started
2004
with 2 others
Phase 3
16 of 46
none open now
Registered
5th of 46
by date
Lead sponsor
29 of 46
Alcon Research

Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the 21st largest by enrollment of the 45 interventional ones that give a count, is one of 3 that started in 2004, is one of 16 in phase 3, and was the 5th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About travoprost

Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing travoprost in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety and effectiveness of an investigational therapy for treating patients with open-angle glaucoma or ocular hypertension.

03

Conditions studied

  • Open-angle Glaucoma
  • Ocular Hypertension

Keywords

  • Open-angle
  • glaucoma
  • ocular
  • hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older.
  • Diagnosis of open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component) or ocular hypertension.
  • Mean IOP in each eye less than 18 mmHg at the screening visit.
  • Other protocol-defined inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Pregnant.
  • History of chronic or recurrent severe inflammatory eye disease.
  • Ocular trauma within the past six months in either eye.
  • Other protocol-defined exclusion criteria may apply.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
156 participants (actual)

Study arms

  • Experimental
    Travoprost 0.004%/Timolol 0.5%

    Travoprost 0.004%/Timolol 0.5% in both eyes each morning at 8 a.m. and Timolol vehicle in both eyes each evening at 8 p.m. for 3 months

    Drug: Travoprost 0.004% / Timolol 0.5% Ophthalmic Solution · Other: Timolol Vehicle

  • Active comparator
    Xalatan + Timolol 0.5%

    Timolol 0.5% in both eyes each morning at 8 a.m. and Xalatan in both eyes each evening at 8 p.m. for 3 months

    Drug: Latanoprost 0.005% Ophthalmic Solution (XALATAN) · Drug: Timolol Maleate Ophthalmic Solution 0.5%

Interventions

  • DrugTravoprost 0.004% / Timolol 0.5% Ophthalmic Solution

    Drug page: Travoprost

    Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension

  • OtherTimolol Vehicle

    Placebo

  • Commercially marketed ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension

    Also known as: XALATAN

  • Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension

06

What researchers measure

Primary outcomes

  1. Mean intraocular pressure (IOP) change at 3 months from baseline

    Time frame: 3 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2004, a primary completion of Aug 2005 and a completion of Aug 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2006
First posted
Feb 20, 2006
Start
Jun 2004
Primary completionActual
Aug 2005
CompletionActual
Aug 2005
Last update
Feb 14, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00293787
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Feb 20, 2006
Start date
Jun 2004
Primary completion
Aug 2005
Completion
Aug 2005
Last update
Feb 14, 2012
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Travoprost

Start the discussion